OMEROS CORP

Omeros Corporation is a commercial-stage biopharmaceutical company that discovers and develops protein and small-molecule therapeutics for complement-mediated diseases, cancers, and addictive disorders. Its approved commercial product is YARTEMLEA, a MASP-2 inhibitor for stem cell transplant-associated thrombotic microangiopathy. Its development pipeline includes complement inhibitors, PDE7 inhibitors for addiction and movement disorders, oncology candidates for leukemia, and infectious disease therapies. The company's customers are stem cell transplant centers, hospitals, and specialized medical teams treating adult and pediatric patients.

Commercial distribution and clinical operations focus primarily on the United States, alongside regulatory review across European Union and European Economic Area member countries. Within the United States, commercial outreach covers 175 stem cell transplant centers, prioritizing the top 80 facilities that conduct roughly 80 percent of procedures. Outside the domestic market, Omeros explores regional and international partnerships. Contract manufacturers perform commercial drug manufacturing, sterile vial filling, and packaging. The text does not disclose the company's headquarters location.

Summary of the business section of Omeros's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 175 full-time employees, 116 of whom are in research and development, 15 of whom are in sales and marketing and 44 of whom are in finance, legal, business development and administration.”